146 related articles for article (PubMed ID: 36351986)
1. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort.
Freise NF; Gliga S; Fischer J; Lübke N; Lutterbeck M; Schöler M; Bölke E; Orth HM; Feldt T; Roemmele C; Wilke D; Schneider J; Wille K; Hohmann C; Strauss R; Hower M; Ruf A; Schubert J; Isberner N; Stecher M; Pilgram L; Vehreschild JJ; ; Hanses F; Luedde T; Jensen B
Sci Rep; 2022 Nov; 12(1):19035. PubMed ID: 36351986
[TBL] [Abstract][Full Text] [Related]
2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
3. Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study.
Rogers R; Shehadeh F; Mylona EK; Rich J; Neill M; Touzard-Romo F; Geffert S; Larkin J; Bailey JA; Lu S; Sweeney J; Mylonakis E
Clin Infect Dis; 2021 Jul; 73(1):e208-e214. PubMed ID: 33038227
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
[TBL] [Abstract][Full Text] [Related]
5. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.
Arnold Egloff SA; Junglen A; Restivo JS; Wongskhaluang M; Martin C; Doshi P; Schlauch D; Fromell G; Sears LE; Correll M; Burris HA; LeMaistre CF
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464352
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
7. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
[TBL] [Abstract][Full Text] [Related]
8. Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study.
Ghadami L; Hasibi M; Asadollahi-Amin A; Asanjarani B; Farahmand M; Abdollahi H
Microb Pathog; 2022 Apr; 165():105482. PubMed ID: 35288278
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of convalescent plasma therapy in severe COVID-19 patients.
Akay Cizmecioglu H; Goktepe MH; Demircioglu S; Tekinalp A; Cizmecioglu A; Tuna AK; Ozer H
Transfus Apher Sci; 2021 Aug; 60(4):103158. PubMed ID: 33994106
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
11. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
12. Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
Ling RR; Sim JJL; Tan FL; Tai BC; Syn N; Mucheli SS; Fan BE; Mitra S; Ramanathan K
Transfus Med Rev; 2022 Jan; 36(1):16-26. PubMed ID: 34782209
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
Diago-Sempere E; Bueno JL; Sancho-López A; Rubio EM; Torres F; de Molina RM; Fernández-Cruz A; de Diego IS; Velasco-Iglesias A; Payares-Herrera C; Flecha IC; Avendaño-Solà C; Palomino RD; Ramos-Martínez A; Ruiz-Antorán B
Trials; 2021 Jan; 22(1):70. PubMed ID: 33472681
[TBL] [Abstract][Full Text] [Related]
14. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
15. Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany.
Koppe U; Schilling J; Stecher M; Rüthrich MM; Marquis A; Diercke M; Haselberger M; Koll CEM; Niebank M; Ruehe B; Borgmann S; Grabenhenrich L; Hellwig K; Pilgram L; Spinner CD; Paerisch T;
BMC Infect Dis; 2023 Feb; 23(1):89. PubMed ID: 36765274
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
17. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)".
Jakob CEM; Borgmann S; Duygu F; Behrends U; Hower M; Merle U; Friedrichs A; Tometten L; Hanses F; Jung N; Rieg S; Wille K; Grüner B; Klinker H; Gersbacher-Runge N; Hellwig K; Eberwein L; Dolff S; Rauschning D; von Bergwelt-Baildon M; Lanznaster J; Strauß R; Trauth J; de With K; Ruethrich M; Lueck C; Nattermann J; Tscharntke L; Pilgram L; Fuhrmann S; Classen A; Stecher M; Schons M; Spinner C; Vehreschild JJ
Infection; 2021 Feb; 49(1):63-73. PubMed ID: 33001409
[TBL] [Abstract][Full Text] [Related]
18. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study.
Hoepler WP; Weidner L; Traugott MT; Neuhold S; Meyer EL; Zoufaly A; Seitz T; Kitzberger R; Baumgartner S; Pawelka E; Karolyi M; Grieb A; Hind J; Laferl H; Friese E; Wenisch C; Aberle SW; Aberle JH; Weseslindtner L; Jungbauer C
Infect Dis (Lond); 2021 Nov; 53(11):820-829. PubMed ID: 34128763
[TBL] [Abstract][Full Text] [Related]
20. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
Tang J; Grubbs G; Lee Y; Golding H; Khurana S
Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
